Bemiparin Sodium

Summary

Bemiparin Sodium (CHEMBL2108806) is a phase-3 clinical-stage oligosaccharide; indicated across 2 conditions including severe acute respiratory syndrome.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Oligosaccharide
• Indications: 2 conditions
• Clinical trials: 5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108806
Name	Bemiparin Sodium
Type	Oligosaccharide
Max phase	3

Also known as: Badyket, Bemiparin sodium, Bemiparina de sodio, Bemiparine sodique, Hibor, Ivor, Zibor, Zivor, BEMIPARINE, BEMIPARIN SODIUM

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
severe acute respiratory syndrome	3	MONDO:0005091	MONDO:0100096

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE3	2
Not specified	2
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02607319	PHASE4	COMPLETED	Low Molecular Weight Heparin to Improve Pregnancy Outcome in Patients With Recurrent Implantation Failure
NCT01880216	PHASE3	COMPLETED	Efficacy of Bemiparin Versus Enoxaparin in the Treatment of DVT
NCT04604327	PHASE3	UNKNOWN	Comparison of Two Different Doses of Bemiparin in COVID-19
NCT02017002	Not specified	UNKNOWN	Comparison of Ivor Lewis and Tri-incision Approaches for Patients With Esophageal Cancer
NCT02808273	Not specified	COMPLETED	Use of Bemiparine as a Prophylactic Antithrombotic Agent, in Patients Undergoing Microsurgery for Head and Neck Reconstruction

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).